Leflunomide protects mice from multiple low dose streptozotocin (MLD- SZ)-induced insulitis and diabetes

Clinical and Experimental Immunology

Volumn 117, Issue 1, 1999, Pages 44-50

  Stosic Grujicic, Stanislava ^a   Dimitrijevic, M ^a   Bartlett, R ^b  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b SANOFI   (France)

Author keywords

Autoimmune disease; Hyperglycaemia; Insulin dependent diabetes mellitus; Leflunomide; Streptozotocin

Indexed keywords

GAMMA INTERFERON; GLUCOSE; LEFLUNOMIDE; NITRIC OXIDE SYNTHASE; STREPTOZOCIN; TERIFLUNOMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; CELL AGGREGATION; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG INDUCED DISEASE; DRUG INHIBITION; HYPERGLYCEMIA; INFLAMMATION; INSULITIS; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MONONUCLEAR CELL; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL;

ANIMALS; AUTOIMMUNE DISEASES; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; ISLETS OF LANGERHANS; ISOXAZOLES; MALE; MICE; MICE, INBRED CBA; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PANCREATITIS; STREPTOZOCIN; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0032972356     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1999.00900.x     Document Type: Article

References (27)

1. Mladenovic V, Domljan Z, Rozman B et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study. Arthr Rheum 1995; 38:1595-603.
2. Thoenes II, Sitter T, Langer KH et al. Leflunomide (HWA 486) inhibits experimental autoimmune tubulointerstitial nephritis in rats. Int J Immunopharmacol 1989; 11:921-9.
3. Ogawa T, Inazu M, Gotoh K, Hayashi S. Effects of leflunomide on glomerulonephritis induced by antibasement membrane antibody in rats. Agents Actions 1990; 31:321-8.
4. Smith-Lang L, Glaser B, Weimer LK et al. Efficacy of novel immunomodulators leflunomide and rapamycin in autoimmune uveitis. FASEB J. 1992; 6:A1048.
5. Schorlemmer HU, Bartlett RR. Therapeutic activity of leflunomide in acute and chronic relapsing experimental allergic encephalomyelitis. Agents Actions 1991; 41:C271-3.
6. Xu X, Blinder L, Shen J et al. In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice. J Immunol 1997; 159:167-74.
7. Dimitrijevic M, Milenkovic M, Milosavljevic P et al. Beneficial effects of leflunomide on cardiac myosin-induced experimental autoimmune myocarditis in rats. Int J Immunother 1998; 14:9-21.
8. Elliot JI, Dewchand H, Altman DM. Streptozotocin-induced diabetes in mice lacking α β T cells. Clin Exp Immunol 1997; 109:116-20.
9. Bartlett RR, Zielinski T, Campion G, Musikic P, Schleyerbach R, Schorlemmer H-U. Leflunomide: A novel immunomodulating drug. In: Lewis AJ, Furst D, eds. Non-Steroidal Anti-Inflammatory Drugs II. New York: Marcel Dekker, Inc., 1994:349-66.
10. Like AA, Rossini AA. Streptozotocin-induced pancreatic insulitis: A new model of diabetes mellitus. Science 1976; 193:415-7.
11. Kwon NS, Lee SH, Choi CS et al. Nitric oxide generation from streptozotocin. FASEB J 1994; 8:529-33.
12. Kolb-Bachofen V, Epstein S, Kiesel U, Kolb H. Low-dose streptozotocin-induced diabetes in mice. Electron microscopy reveals single-cell insulitis before diabetes onset. Diabetes 1988; 37:21-27.
13. Herold KC, Vezys V, Sun Q et al. Regulation of cytokine production during development of autoimmune diabetes induced with multiple low doses of streptozotocin. J Immunol 1996; 156:3521-7.
14. Lukic ML, Stosic-Grujicic S, Shahin A. Effector mechanisms in low dose streptozotocin induced diabetes. Dev Immunol 1998; 6:119-28.
15. Rothlein R, Springer TA. The requirement for leukocyte function-associated antigen 1 in homotypic leukocyte adhesion stimulated by phorbol ester. J Exp Med 1986; 163:1132-49.
16. Lukic ML, Stocic-Grujicic S, Ostojic N et al. Inhibition of nitric oxide generation affects the induction of diabetes by streptozotocin in mice. Biochem Biophys Res Commun 1991; 178:913-20.
17. Stocic-Grujicic S, Dimitrijevic M, Bartlett RR. A novel immunomodulating agent - Leflunomide inhibits experimental autoimmune diabetes in mice. Transplant Proc 1996; 28:3072-3.
18. Dimitrijevic M, Bartlett RR. Leflunomide, a novel immunomudulating drug, inhibits homotypic adhesion of peripheral blood and synovial fluid mononuclear cells in rheumatoid arthritis. Inflamm Res 1996; 45:550-6.
19. Elder RT, Xu X, Williams JW et al. The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms. J Immunol 1997; 159:22-27.
20. Brazelton TR, Moris RE. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: Tacrolimus (FK506), sirolimus (rapamycin) mycophenolate mofetil and leflunomide. Curr Opin Immunol 1996; 8:710-20.
21. Herold KC, Vezys V, Koons A et al. CD28/B7 costimulation regulates autoimmune diabetes induced with multiple low doses of streptozotocin. J Immunol 1997; 158:984-91.
22. Ilogg N, Berlin C. Structure and function of adhesion receptors in leukocyte trafficking. Immunol Today 1995; 16:327-30.
23. Feve B, Segain JP, Charbonnel B, Sai P. β-cell adherent splenocytes precede the onset of diabetes in low-dose streptozotocin-treated mice. Diabetologia 1990; 39:9-14.
24. Dahlen E, Dawe K, Ohlsson L, Hedlund C. TNF-α in pancreatic islets in the nonobese diabetic mouse. J Immunol 1998; 160:3583-93.
25. Corbett JA, McDaniel MI. Intraislet release of interleukin I inhibits β cell function by inducing β cell expression of inducible nitric oxide synthase. J Exp Med 1995; 181:559-68.
26. Stassi G, De Maria R, Trucco G et al. Nitric oxide primes pancreatic β cells for Fas-mediated destruction in insulin-dependent diabetes mellitus. J Exp Med 1997; 186:1193-200.
27. Dong Z, Qi X, Xie K et al. Protein tyrosine kinase inhibitors decrease induction of nitric oxide synthase activity in lipopolysaccharide-responsive and lipopolysaccharide-nonresponsive murine macrophages. J Immunol 1993; 151:2717-24.